Valuation: Arcus Biosciences, Inc.

Market Cap 2.43B 2.17B 2.01B 1.82B 3.42B 230B 3.46B 24.06B 9.44B 121B 9.12B 8.93B 384B P/E 2026 *
-5.39x
P/E 2027 * -5.74x
Enterprise Value 1.99B 1.77B 1.64B 1.49B 2.8B 188B 2.83B 19.7B 7.73B 98.78B 7.47B 7.31B 315B EV / Sales 2026 *
27.2x
EV / Sales 2027 * 41.2x
Free-Float
71.2%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Arcus Biosciences, Inc.

1 day-19.58%
1 week-15.22%
Current month-26.05%
1 month-26.40%
3 months-35.21%
6 months-22.10%
Current year-19.85%
1 week 18.98
Extreme 18.98
24.7
1 month 18.98
Extreme 18.98
27.9
Current year 18.52
Extreme 18.515
31.74
1 year 16.41
Extreme 16.41
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 2015-04-30
Chief Executive Officer 67 2015-04-30
Director of Finance/CFO 53 2020-07-31
Director TitleAgeSince
Chairman 67 2017-11-30
Director/Board Member 65 2017-09-17
Director/Board Member 72 2015-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Exercice

Controller/Auditor

8,481 0.0067%
7/10/26 Sell

Founder

-20,067 0.0160%
6/11/26 Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
-19.58%-15.22%+5.82%+18.49% 2.43B
-0.21%-4.43%+44.40%+74.13% 66.22B
-3.43%+0.05%+7.02%+68.33% 55.2B
+0.22%+3.44%+11.54%+90.66% 52.79B
+3.28%+5.58%+26.51%+50.05% 45.53B
+0.51%+9.95%+22.40%+133.92% 43.94B
-1.15%+0.39%+263.21%+594.60% 41.64B
+0.10%+9.90%+16.11%+59.33% 34B
-8.38%-6.95%+26.35%-1.93% 25.84B
-0.10%+2.97%+35.62%+25.62% 23.51B
Average -2.88%+2.14%+45.90%+111.32% 39.11B
Weighted average by Cap. -0.86%+3.61%+49.01%+125.30%

Financials

2026 *2027 *
Net sales 73.15M 65.18M 60.35M 54.61M 103M 6.9B 104M 724M 284M 3.63B 274M 269M 11.56B 56.52M 50.36M 46.63M 42.19M 79.5M 5.33B 80.44M 559M 219M 2.8B 212M 208M 8.93B
Net income -449M -400M -370M -335M -631M -42.36B -639M -4.44B -1.74B -22.27B -1.68B -1.65B -70.95B -413M -368M -341M -308M -581M -38.99B -588M -4.09B -1.6B -20.5B -1.55B -1.52B -65.31B
Net Debt -441M -393M -364M -329M -620M -41.58B -627M -4.36B -1.71B -21.86B -1.65B -1.62B -69.65B -102M -91.03M -84.28M -76.27M -144M -9.64B -145M -1.01B -397M -5.07B -383M -375M -16.15B
Projected Income Statement - Annual - Arcus Biosciences, Inc.
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
26-10-21 $19.10 -19.58% 4,654,346
26-10-20 $23.75 +7.27% 6,242,268
26-10-19 $22.14 +0.09% 3,516,696
26-10-16 $22.12 -3.07% 1,425,533
26-10-15 $22.82 +1.29% 1,210,181
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Arcus Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
19.10USD
Average target price
41.69USD
Spread / Average Target
+118.28%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arcus Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. RCUS Stock